Table 1 Patient characteristics
From: Hypouricemic effect and safety of febuxostat used for prevention of tumor lysis syndrome
Febuxostat | Allopurinol | P value | |
|---|---|---|---|
No. of patients | 38 | 39 | |
Agea | 62.5 (26–83) | 64 (25–79) | 0.46 |
Body weightb, kg | 61 ± 12 | 53 ± 12 | 0.0051 |
Diseasec, n | 0.24 | ||
Acute myeloid leukemia | 10 | 10 | |
Acute lymphoblastic leukemia | 0 | 4 | |
Non-Hodgkin lymphoma | |||
aggressive B-cell | 6 | 10 | |
indolent B-cell | 11 | 9 | |
T-cell | 4 | 3 | |
Others | 7 | 3 | |
Serum creatinineb, mg/dL | 0.90 ± 0.39 | 0.76 ± 0.30 | 0.071 |
Renal dysfunctionc, n (%) | 0.0073 | ||
Yes | 14 (37%) | 4 (10%) | |
TLS riskc, n | 0.30 | ||
Low | 18 | 12 | |
Intermediate | 18 | 24 | |
High | 2 | 3 | |
Serum LDHb, IU/L | 395 ± 360 | 468 ± 542 | 0.49 |
Serum uric acidb, mg/dL | |||
Overall | 5.8 ± 2.3 | 5.4 ± 1.6 | 0.41 |
Patients not receiving rasburicase | 5.6 ± 2.1 | 5.4 ± 1.6 | 0.73 |